Growing Adoption of AI Based Tools - A Boon to the Global Drug Discovery Services Market


Posted February 16, 2021 by mmvaidya

Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process
 
Recent Developments:

# In 2020, Covance entered into a partnership with Medable to expedite the adoption of decentralized trial technology.

# In 2020, Eurofins entered into partnership with PharmaResources (China). This partnership enabled both companies to build a joint drug discovery platform to accelerate small molecule drug development.

# In 2020, LabCorp launched its extensive preclinical, clinical, and post-approval cell and gene therapy development solutions through Covance, its drug development business.

# In 2020, WuXi AppTec Research Service Division and BioSolveIT launched GalaXi, a new chemical space of tangible molecules.

# In 2020, Charles River acquired HemaCare to strengthen its Research Models Services segment through Hemacare’s broad range of human primary cell and cell processing services that support the discovery and development of cell therapies.

Medicinal Chemistry accounted for the largest share the drug discovery technology market in 2019

Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). Of all these type segments, the medicinal chemistry services segment accounted for the largest share of the drug discovery services market in 2019 The large share of this segment is due to factors such as the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates. Furthermore, the extensive usage of medicinal chemistry in academics, biotechnology companies, and large pharmaceutical companies are also supporting market growth.

North America accounted for largest share of the drug discovery services market in 2019.

Based on the region, the global drug discovery technology market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the drug discovery services market. The large share of this market segment can be attributed majorly to the presence of well-established CROs, rising R&D expenditure by pharmaceutical & biopharmaceutical companies, and the availability of latest techniques, instruments, and facilities for drug discovery research.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129

Global Leaders:

The major players operating in drug discovery services market market Laboratory Corporation of America Holdings (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec A.G. (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Thermo Fisher Scientific, Inc. (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), and Selvita S.A. (Poland) among others.

Expected Revenue Growth:

The global drug discovery technology market size is projected to reach USD 21.4 billion by 2025 from USD 11.1 billion in 2020, at a CAGR of 14.0% during the forecast period.

Major Revenue Growth Boosters:

Market growth is largely driven by the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and the focus on drug discovery.

Small molecule drugs accounted for largest share in drug discovery services market in 2019.

Based on drug type, the drug discovery services market is segmented into small-molecule drugs and biologic drugs. In 2019, small molecule drugs accounted for the largest market share as small-molecule drugs are simple, well-defined, and easy t’o characterize. Due to these features, they can quickly enter cells, affect molecules, and cause cancer cells to die.

Oncology segment accounted for the largest share in the drug discovery services market in 2019

Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. The oncology segment accounted for the largest market share in 2019, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.

Report Objectives:

# To define, describe, and forecast the global drug discovery services market on the basis of process, type, drug type, therapeutic area, company type, and region.

# To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and trends).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall drug discovery services market.

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders operating in the drug discovery services market.

# To forecast the revenue of the market with respect to four regional segments, namely, North America, Europe, the Asia Pacific, and the Rest of The World.

# To profile key market players and comprehensively analyze their service portfolios, market positions, and core competencies.

# To track and analyze competitive developments such as services launches; expansions; agreements, collaborations, & partnerships; and mergers & acquisitions in the drug discovery technology market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Makarand Vaidya
Country United States
Categories Industry , Medical , News
Tags drug discovery technology , drug discovery technology industry , drug discovery technology market , global drug discovery technology industry , global drug discovery technology market
Last Updated February 16, 2021